Skip to main content
Premium Trial:

Request an Annual Quote

Life at Lilly

It's tough times at Eli Lilly with patents ending, failed drugs, among other problems, reports the New York Times. But CEO John Lechleiter says that Lilly doesn't need to turn to mergers or acquisitions to jump-start the company; he says they can rely on in-house research and cost-cutting. "At a time when others say Lilly has to do a deal or Lilly has to go outside itself to solve its problems, we're resolutely focused on what we have to do inside the company," Lechleiter says. The Times points out that "some analysts do not share his optimism" as the company has "virtually no new products to market until 2013, when it hopes to start rolling out two a year."

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.